Review
BibTex RIS Cite

KANSER HÜCRE METABOLİZMASI

Year 2021, , 66 - 75, 31.12.2021
https://doi.org/10.54537/tusebdergisi.981144

Abstract

Kanser, büyüme ve gelişimi sağlayan kontrol mekanizmalarının bozulması sonucu hücrenin kontrolsüz bölünmesiyle meydana gelen doku veya organlarda görülen bir hastalık türüdür. Dünya’da en çok görülen ölüm nedenleri arasında ikinci sıradadır. Kanserli hücreler hızla bölündüklerinden dolayı normal hücrelere göre daha fazla besin alma ihtiyacı hissederler. Bu sebeple kullandıkları besinlerle metabolizmalarında değişikliğe giderler. Bu derlemedeki amacımız kanser hücrelerinin glukoz, glutamin ve lipit metabolizmalarının normal hücre metabolizmalarından farkını açıklamak ve bu farklılıkların kanser gelişimine etkisini göstermektir.

References

  • Maniam S, Maniam S. (2020). Cancer Cell Metabolites: Updates on Current Tracing Methods. ChemBioChem, 21, 3476 – 3488
  • Kato Y., Maedaa T., Suzuki A., vd. (2017). Cancer metabolism: New insights into classic characteristics Japanese Dental Science Review.54, 8-21
  • Ramapriyan R., Caetano M.S., H.B. Barsoumian, vd. (2019). Altered cancer metabolism in mechanisms of immunotherapy resistance. Pharmacology & Therapeutics, 195, 162-171.
  • Garcia-Bermudez J., Williams R.T., Guarecuco R., vd. (2019). Targeting extracellular nutrient dependencies of cancer cells. Molecular Metabolism 33,67-82
  • Thorens B. ve Mueckler M. (2010). Glucose Transporters in the 21st Century.AJP, 298:2, 141-145.
  • Jun YJ, Jang SM, Han HL, vd. (2011). Clinicopathologic significance of GLUT1 expression and its correlation with apaf-1 in colorectal adenocarcinomas. World J Gastroenterol, 17:1866–1873.
  • Thorens B. (1992). Molecular and cellular physiology of GLUT2, a high-Km facilitated diffusion glucose transporter. Int Rev Cytol 137A: 209–238
  • Augustin R. (2010). The protein family of glucose transport facilitators: it’s not only about glucose after all. IUBMB Life 62:315–333.
  • Van der Heiden MG, Cantley L.C. ve Thompson CB. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324:1029–1033.
  • Warburg O. (1956). On the origin of cancer cells. Science 123: 309-314
  • Weinhouse S. (1976).The Warburg hypothesis fifty years later. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 87:115–126.
  • Rodríguez C., Puente‐Moncada N., Reiter R. J., vd. (2021). Regulation of cancer cell glucose metabolism is determinant for cancer cell fate after melatonin administration. J Cell Physiol., 236:27–40.
  • Anderson N.M,.Mucka P, Kern J.G, vd. (2018). The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell. 9 (2), 216-237.
  • Valle-Mendiola A. ve Soto-Cruz I. (2020). Energy Metabolism in Cancer: The Roles of STAT3 and STAT5 in the Regulation of Metabolism-Related Genes. Cancers, 12;124,1-23.
  • Pavlova N.N ve Craig B.(2016).The emerging hallmarks of cancer metabolism. Cell Metab. Jan 12; 23(1): 27–47.
  • Hamanaka R.B. ve Chandel NS. (2012).Targeting glucose metabolism for cancer therapy. J Exp Med,209(2):211-5.
  • Zhang XD, Qin ZH. ve Wang J. (2010).The role of p53 in cell metabolism. Acta Pharmacol Sin;31(9):1208-12.
  • Kisaçam M.A. ve Temizer Ozan P.S. (2019). Kanser Hücrelerinin Metabolik İhtiyaçları ve Bağımlılıkları. F.Ü.Sağ.Bil.Vet.Derg.; 31 (1): 67 – 72.
  • Granchi C, Fancelli D. ve Minutolo F. (2014).An update on therapeutic opportunities offered by cancer glycolytic metabolism. Bioorg Med Chem Lett; 24:4915-4925.
  • Salamon S, Podbregar E, Kubatkac P., vd. (2017). Glucose metabolism in cancer and ischemia: Possible therapeutic consequences of the warburg effect. Nutr Cancer 69: 177-183.
  • Erdamar H., Hacıevliyagil Kazancı F. ve Gök S. (2015). Kanserde Biyokimyasal Değişiklikler. JCAM, 1-9.
  • Park J.H, W.Y.Pyun ve Park H.W., (2020). Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets. Cells 9, 2308;1-31
  • Cruzat V., Rogero M.M., Keane K.N., Curi R., vd. (2018). Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation. Nutrients, 10(11): 1564.
  • Holecek M. (2018). Branched-chain amino acids in health and disease: Metabolism, alterations in blood plasma, and as supplements. Nutr. Metab.15:33
  • Cluntun A.A., Lukey M.J., Cerione R.A., ve Locasale J.W. (2018).Glutamine Metabolism in Cancer: Understanding the Heterogeneity, Trends Cancer. 3(3): 169–180.
  • Noe JE. (2009). L-Glutamine use in the treatment and prevention of mucositis and cachexia: a naturopathic perspective. Integrative Cancer Therapies. 8(4): 409-415.
  • Daye D. ve Wellen KE. (2012). Metabolic reprogramming in cancer: Unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol 23: 362-369.
  • DeBerardinis RJ, Mancuso A, Daikhin E, vd. (2007). Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci, 104: 19345-19350.
  • Gao P, Tchernyshyov I, Chang TC., vd. (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458: 762-765.
  • Le A, Lane AN, Hamaker M, vd. (2012). Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 15: 110-121.
  • Ünal İ. (2010). Radyoterapi uygulanan pelvik malign tümörlü hastalarda profilaktik oral glutamin kullanımının yaşam kalitesi üzerine etkisinin değerlendirilmesi. Uzmanlık tezi, Hacettepe Üniversitesi, Radyasyon Onkolojisi Anabilim Dalı, Ankara,
  • Harvey R. ve Ferrier D. (2015).Lippincot Biyokimya 5. Baskı, İstanbul.
  • Huang C. Ve Freter C. (2015). Lipid metabolism, apoptosis and cancer therapy. International journal of molecular sciences. 16(1), 924–949.
  • Salvador M., Gómez de Cedrón M., Rubio M.M., J., vd. (2017).M. Lipid metabolism and lung cancer. Critical reviews in oncology/hematology. 112, 31–40.
  • Parrales, A. ve Iwakuma, T. (2016). p53 as a Regulator of Lipid Metabolism in Cancer. International journal of molecular sciences. 17(12), 2074. Brault, C. ve Schulze, A. (2016).The Role of Glucose and Lipid Metabolism in Growth and Survival of Cancer Cells. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 207, 1–22.
  • Yang J., Wang L., ve Jia R. (2020). Role of de novo cholesterol synthesis enzymes in cancer. Journal of Cancer,11:1761-1767.
Year 2021, , 66 - 75, 31.12.2021
https://doi.org/10.54537/tusebdergisi.981144

Abstract

References

  • Maniam S, Maniam S. (2020). Cancer Cell Metabolites: Updates on Current Tracing Methods. ChemBioChem, 21, 3476 – 3488
  • Kato Y., Maedaa T., Suzuki A., vd. (2017). Cancer metabolism: New insights into classic characteristics Japanese Dental Science Review.54, 8-21
  • Ramapriyan R., Caetano M.S., H.B. Barsoumian, vd. (2019). Altered cancer metabolism in mechanisms of immunotherapy resistance. Pharmacology & Therapeutics, 195, 162-171.
  • Garcia-Bermudez J., Williams R.T., Guarecuco R., vd. (2019). Targeting extracellular nutrient dependencies of cancer cells. Molecular Metabolism 33,67-82
  • Thorens B. ve Mueckler M. (2010). Glucose Transporters in the 21st Century.AJP, 298:2, 141-145.
  • Jun YJ, Jang SM, Han HL, vd. (2011). Clinicopathologic significance of GLUT1 expression and its correlation with apaf-1 in colorectal adenocarcinomas. World J Gastroenterol, 17:1866–1873.
  • Thorens B. (1992). Molecular and cellular physiology of GLUT2, a high-Km facilitated diffusion glucose transporter. Int Rev Cytol 137A: 209–238
  • Augustin R. (2010). The protein family of glucose transport facilitators: it’s not only about glucose after all. IUBMB Life 62:315–333.
  • Van der Heiden MG, Cantley L.C. ve Thompson CB. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324:1029–1033.
  • Warburg O. (1956). On the origin of cancer cells. Science 123: 309-314
  • Weinhouse S. (1976).The Warburg hypothesis fifty years later. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 87:115–126.
  • Rodríguez C., Puente‐Moncada N., Reiter R. J., vd. (2021). Regulation of cancer cell glucose metabolism is determinant for cancer cell fate after melatonin administration. J Cell Physiol., 236:27–40.
  • Anderson N.M,.Mucka P, Kern J.G, vd. (2018). The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell. 9 (2), 216-237.
  • Valle-Mendiola A. ve Soto-Cruz I. (2020). Energy Metabolism in Cancer: The Roles of STAT3 and STAT5 in the Regulation of Metabolism-Related Genes. Cancers, 12;124,1-23.
  • Pavlova N.N ve Craig B.(2016).The emerging hallmarks of cancer metabolism. Cell Metab. Jan 12; 23(1): 27–47.
  • Hamanaka R.B. ve Chandel NS. (2012).Targeting glucose metabolism for cancer therapy. J Exp Med,209(2):211-5.
  • Zhang XD, Qin ZH. ve Wang J. (2010).The role of p53 in cell metabolism. Acta Pharmacol Sin;31(9):1208-12.
  • Kisaçam M.A. ve Temizer Ozan P.S. (2019). Kanser Hücrelerinin Metabolik İhtiyaçları ve Bağımlılıkları. F.Ü.Sağ.Bil.Vet.Derg.; 31 (1): 67 – 72.
  • Granchi C, Fancelli D. ve Minutolo F. (2014).An update on therapeutic opportunities offered by cancer glycolytic metabolism. Bioorg Med Chem Lett; 24:4915-4925.
  • Salamon S, Podbregar E, Kubatkac P., vd. (2017). Glucose metabolism in cancer and ischemia: Possible therapeutic consequences of the warburg effect. Nutr Cancer 69: 177-183.
  • Erdamar H., Hacıevliyagil Kazancı F. ve Gök S. (2015). Kanserde Biyokimyasal Değişiklikler. JCAM, 1-9.
  • Park J.H, W.Y.Pyun ve Park H.W., (2020). Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets. Cells 9, 2308;1-31
  • Cruzat V., Rogero M.M., Keane K.N., Curi R., vd. (2018). Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation. Nutrients, 10(11): 1564.
  • Holecek M. (2018). Branched-chain amino acids in health and disease: Metabolism, alterations in blood plasma, and as supplements. Nutr. Metab.15:33
  • Cluntun A.A., Lukey M.J., Cerione R.A., ve Locasale J.W. (2018).Glutamine Metabolism in Cancer: Understanding the Heterogeneity, Trends Cancer. 3(3): 169–180.
  • Noe JE. (2009). L-Glutamine use in the treatment and prevention of mucositis and cachexia: a naturopathic perspective. Integrative Cancer Therapies. 8(4): 409-415.
  • Daye D. ve Wellen KE. (2012). Metabolic reprogramming in cancer: Unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol 23: 362-369.
  • DeBerardinis RJ, Mancuso A, Daikhin E, vd. (2007). Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci, 104: 19345-19350.
  • Gao P, Tchernyshyov I, Chang TC., vd. (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458: 762-765.
  • Le A, Lane AN, Hamaker M, vd. (2012). Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 15: 110-121.
  • Ünal İ. (2010). Radyoterapi uygulanan pelvik malign tümörlü hastalarda profilaktik oral glutamin kullanımının yaşam kalitesi üzerine etkisinin değerlendirilmesi. Uzmanlık tezi, Hacettepe Üniversitesi, Radyasyon Onkolojisi Anabilim Dalı, Ankara,
  • Harvey R. ve Ferrier D. (2015).Lippincot Biyokimya 5. Baskı, İstanbul.
  • Huang C. Ve Freter C. (2015). Lipid metabolism, apoptosis and cancer therapy. International journal of molecular sciences. 16(1), 924–949.
  • Salvador M., Gómez de Cedrón M., Rubio M.M., J., vd. (2017).M. Lipid metabolism and lung cancer. Critical reviews in oncology/hematology. 112, 31–40.
  • Parrales, A. ve Iwakuma, T. (2016). p53 as a Regulator of Lipid Metabolism in Cancer. International journal of molecular sciences. 17(12), 2074. Brault, C. ve Schulze, A. (2016).The Role of Glucose and Lipid Metabolism in Growth and Survival of Cancer Cells. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 207, 1–22.
  • Yang J., Wang L., ve Jia R. (2020). Role of de novo cholesterol synthesis enzymes in cancer. Journal of Cancer,11:1761-1767.
There are 36 citations in total.

Details

Primary Language Turkish
Subjects Industrial Biotechnology
Journal Section Derlemeler
Authors

Saniye Ada This is me

Cemre Ertürk This is me

Aylin Uçar This is me

Süleyman Akyüz

Fatma Doğan This is me

Burcu Yücel

Publication Date December 31, 2021
Published in Issue Year 2021

Cite

APA Ada, S., Ertürk, C., Uçar, A., Akyüz, S., et al. (2021). KANSER HÜCRE METABOLİZMASI. Türkiye Sağlık Enstitüleri Başkanlığı Dergisi, 4(3), 66-75. https://doi.org/10.54537/tusebdergisi.981144

Cited By